Last reviewed · How we verify
TDV - High Dose
At a glance
| Generic name | TDV - High Dose |
|---|---|
| Also known as | Live attenuated tetravalent dengue vaccine |
| Sponsor | Inviragen Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore (PHASE2)
- Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDV - High Dose CI brief — competitive landscape report
- TDV - High Dose updates RSS · CI watch RSS
- Inviragen Inc. portfolio CI